ACB-PCR Quantification of K-RAS Codon 12 GAT and GTT Mutant Fraction in Colon Tumor and Non-Tumor Tissue

REFERENCES

• Lilleberg, S.L.; Durocher, J.; Sanders, C.; Walters, K.; Culver, K. High sensitivity scanning of colorectal tumors and matched plasma DNA for mutations in APC, TP53, K-RAS, and BRAF genes with a novel DHPLC fluorescence detection platform. Ann N Y Acad Sci 2004, 1022, 250–256.
   PubMed Web of Science ®Google Scholar
• Bazan, V.; Bruno, L.; Augello, C.; Molecular detection of TP53, Ki-Ras and p16INK4A promoter methylation in plasma of patients with colorectal cancer and its association with prognosis. Results of a 3-year GOIM (Gruppo Oncologico dell’Italia Meridionale) prospective study. Ann Oncol 2006, 17(Suppl. 7), vii84–vii90.
   PubMedGoogle Scholar
• Ito, Y.; Kobayashi, S.; Taniguchi, T.; Kainuma, O.; Hara, T.; Ochiai, T. Frequent detection of K-ras mutation in stool samples of colorectal carcinoma patients after improved DNA extraction: comparison with tissue samples. Int J Oncol 2002, 20, 1263–1268.
   PubMed Web of Science ®Google Scholar
• Lecomte, T.; Berger, A.; Zinzindohoue, F.; Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis. Int J Cancer 2002, 100, 542–548.
   PubMed Web of Science ®Google Scholar
• Andreyev, H.J.N.; Norman, A.R.; Cunningham, D.; Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study. Br J Cancer 2001, 85, 692–696.
   PubMed Web of Science ®Google Scholar
• Font, A.; Abad, A.; Monzo, M.; Prognostic value of K-ras mutations and allelic imbalance on chromosome 18q in patients with resected colorectal cancer. Dis Colon Rectum 2001, 44, 549–557.
   PubMed Web of Science ®Google Scholar
• Hassan, A.B.; Paraskeva, C. Colorectal cancer prognosis: is it all mutation, mutation, mutation? Gut 2005, 54, 1209–1211.
   PubMed Web of Science ®Google Scholar
• Lievre, A.; Bachet, J.-B.; Le Corre, D.; K-RAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006, 66, 3992–3995.
   PubMed Web of Science ®Google Scholar
• Han, S.W.; Kim, T.Y.; Jeon, Y.K.; Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation. Clin Cancer Res (an official journal of the American Association for Cancer Research) 2006, 12, 2538–2544.
   PubMed Web of Science ®Google Scholar
• Zhang, H.; Nordenskjold, B.; Dufmats, M.; Soderkvist, P.; Sun, X.-F. K-ras mutations in colorectal adenocarcinomas and neighbouring transitional mucosa. Eur J Cancer 1998, 34, 2053–2057.
   PubMed Web of Science ®Google Scholar
• Yamada, S.; Yashiro, M.; Maeda, K.; Nishiguchi, Y.; Hirakawa, K. A novel high-specificity appraoch for colorectal neoplasia: detection of K-ras2 oncogene mutation in normal mucosa. Int J Cancer 2005, 113, 1015–1020.
   PubMed Web of Science ®Google Scholar
• Ronai, Z.; Luo, F.C.; Gradia, S.; Hart, W.J.; Butler, R. Detection of K-ras mutation in normal and malignant colonic tissues by an enriched PCR method. Int J Onc 1994, 4, 391–396.
   PubMed Web of Science ®Google Scholar
• Zhu, D.; Keohavong, P.; Finkelstein, S.D.; K-ras gene mutations in normal colorectal tissues from K-ras mutation-positive colorectal cancer patients. Cancer Res 1997, 57, 2485–2492.
   PubMed Web of Science ®Google Scholar
• Kraus, M.C.; Seelig, M.H.; Linnemann, U.; Berger, M.R. The balanced induction of K-ras codon 12 and 13 mutations in mucosa differs from their ratio in neoplastic tissues. Int J Onc 2006, 29, 957–964.
   PubMed Web of Science ®Google Scholar
• Imperiale, T.F.; Ransohoff, D.F.; Itzkowitz, S.H.; Turnbull, B.A.; Ross, M.E. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med 2004, 351, 2704–2714.
   PubMed Web of Science ®Google Scholar
• Rennert, G.; Kislitsin, D.; Brenner, D.E.; Rennert, H.S.; Lev, Z. Detecting K-ras mutations in stool from fecal occult blood test cards in multiphasic screening for colorectal cancer. Cancer Lett 2007, 253, 258–264.
   PubMed Web of Science ®Google Scholar
• Loktionov, A.; O’Neill, I.K.; Silvester, K.R.; Cummings, J.H.; Middleton, S.J.; Miller, R. Quantitation of DNA from exfoliated colonocytes isolated from human stool surface as a novel noninvasive screening test for colorectal cancer. Clin Cancer Res 1998, 4, 337–342.
   PubMed Web of Science ®Google Scholar
• Yamada, S.; Yashiro, M.; Maeda, K.; Nishiguchi, Y.; Hirakawa, K. A novel high-specificity approach for colorectal neoplasia: detection of K-ras2 oncogene mutation in normal mucosa. Int J Cancer 2005, 113, 1015–1021.
   PubMed Web of Science ®Google Scholar
• Dieterle, C.P.; Conzelmann, M.; Linnemann, U.; Berger, M.R. Detection of isolated tumor cells by polymerase chain reaction-restriction fragment length polymorphism for K-ras mutations in tissue samples of 199 colorectal cancer patients. Clin Cancer Res 2004, 10, 641–650.
   PubMed Web of Science ®Google Scholar
• McKinzie, P.B.; Parsons, B.L. Detection of rare K-ras codon 12 mutations using allele-specific competitive blocker PCR. Mutat Res – Genet Toxicol Environ Mutagen 2002, 517, 209–220.
   PubMed Web of Science ®Google Scholar
• Parsons, B.L.; McKinzie, P.B.; Heflich, R.H. ACB-PCR detection of rare point mutation. In Molecular Toxicology Protocols, Methods in Molecular Biology, P. Keohavong, (ed.). Totowa, NJ: Humana Press, 2005, pp. 235–245.
   Google Scholar
• Vitale-Cross, L.; Amornphimoltham, P.; Fisher, G.; Molinolo, A.A.; Gutkind, J.S. Conditional expression of K-ras in an epithelial compartment that includes the stem cells is sufficient to promote squamous cell carcinogenesis. Cancer Res 2004, 64, 8804–8807.
   Google Scholar
• Arena, S.; Isella, C.; Martini, M.; De Marco, A.; Medico, E.; Bardelli, A. Knock-in of oncogenic K-ras does not transform mouse somatic cells but triggers a transcriptional response that classifies human cancers. Cancer Res 2007, 67, 8468–8476.
   PubMed Web of Science ®Google Scholar
• Janssen, K.P.; Abal, M.; El Marjou, F.; Louvard, D.; Robine, S. Mouse models of K-ras-initiated carcinogenesis. Biochim Biophys Acta 2005, 1756, 145–154.
   PubMed Web of Science ®Google Scholar
• Novelli, M.R.; Williamson, J.A.; Tomlinson, I.P.; Polyclonal origin of colonic adenomas in an XO/XY patient with FAP. Science 1996, 272, 1187–1190.
   PubMed Web of Science ®Google Scholar
• Merritt, A.J.; Gould, K.A.; Dove, W.F. Polyclonal structure of intestinal adenomas in APC min/ +mice with concomitant loss of Apc+ from all tumor lineages. Proc Natl Acad Sci USA 1997, 94, 13927–13931.
   PubMed Web of Science ®Google Scholar
• Thliveris, A.T.; Halberg, R.B.; Clipson, L.; Polyclonality of familial murine adenomas: analyses of mouse chimeras with low tumor multiplicity suggest short-range interactions. Proc Natl Acad Sci USA 2005, 102, 6960–6965.
   PubMed Web of Science ®Google Scholar
• Newton, M.A.; Clipson, L.; Thliveris, A.T.; Halberg, R.B. A statistical test of the hypothesis that polyclonal intestinal tumors arise by random collision of initiated clones. Biometrics 2006, 62, 1–7.
   PubMedGoogle Scholar
• Halberg, R.B.; Dove, W.F. Polyclonal tumors in the mammalian intestine: are interactions among multiple initiated clones necessary for tumor initiation, growth, and progression? Cell Cycle 2007, 6, 44–51.
   PubMed Web of Science ®Google Scholar
• Humpfries, A.; Wright, N.A. Colonic crypt organization and tumorigenesis. Nat Rev Cancer 2008, 8, 415–424.
   PubMed Web of Science ®Google Scholar
• Parsons, B.L. Many different tumor types have polyclonal origin: evidence and implications. Mutat Res – Rev Mutat Res 2008, 659, 232–247.
   PubMed Web of Science ®Google Scholar
• De Roock, W.; Piessevaux, H.; De Schutter, J.; KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2008, 19, 508–515.
   PubMed Web of Science ®Google Scholar
• Lievre, A.; Bachet, J.-B.; Boige, V.; K-RAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008, 26, 374–379.
   PubMed Web of Science ®Google Scholar
• Forbes, S.A.; Bhamra, G.; Bamford, S.; The catalogue of somatic mutations in cancer (COSMIC), unit 10.11. Curr Protoc Hum Genet 2008, 57, 10.11.11–10.11.26.
   Google Scholar
• Suehiro, Y.; Hinoda, Y. Genetic and epigenetic changes in aberrant crypt foci and serrated polyps. Cancer Sci 2008, 99, 1071–1076.
   PubMed Web of Science ®Google Scholar
• Parsons, B.L.; Meng, F.K. RAS mutation in the screening, prognosis, and treatment of cancer. Biomarkers Med 2009, 3, 757–769.
   PubMed Web of Science ®Google Scholar
• Osborn, N.K.; Ahlquist, D.A. Stool screening for colorectal cancer: molecular approaches. Gastroenterology 2005, 128, 192–206.
   PubMed Web of Science ®Google Scholar